Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. is engaged in research, development, manufacture, and marketing of proprietary respiratory support technology. The firm seeks to provide alternative to invasive mechanical ventilation. The company was founded by Dagi Ben Noon, Joe Hayon, and Dr. Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.

Inspira (IINN) Expands in Life Support Space With New Deal

RA'ANANA, Israel , Nov. 29, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), an innovator in life support technology, is excited to announce a partnership with Ennocure MedTech Ltd.

Inspira Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

RA'ANANA, Israel , Nov. 16, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in acute respiratory care, today announced its financial results for the third quarter ended September 30, 2023.

Inspira™ Technologies Reports Third Quarter 2023 Financial Results

Inspira's VORTX is as a potential frontrunner in the $4 Billion Disposable Blood Oxygenator market  RA'ANANA, Israel , Nov. 6, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company dedicated to transforming the multi-billion dollar acute respiratory care market with the INSPIRA ART medical device line, is pleased to announce the recent approval of a grant from the Israeli Innovation Authority (IIA) for the groundbreaking VORTX™ Disposable Blood Oxygenation Technology.

Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology

This new patent advances Inspira's ability to enter into the Company estimated $20 billion market as a potential innovative frontrunner with planned global deployments of its exclusive INSPIRA ART500 and disruptive technology. RA'ANANA, Israel , Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd.

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

RA'ANANA, Israel , Oct. 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) - ("Inspira Technologies" or "the Company"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, today announces the termination of its at-the-market (ATM) equity offering program originally announced on April 4, 2023, taking effect immediately.

Inspira™ Terminates ATM Program and Provides an Update

The agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over a five year period following a regulatory approval RA'ANANA, Israel , Oct. 10, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs to minimize the need for mechanical ventilation systems, announced today that it had signed a distribution agreement (the "Agreement") with CIO MED GROUP, CORP.

Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP

The ELSO conference brings together healthcare institutions, researchers, and industry partners RA'ANANA, Israel , Sept. 28, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.

Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference

Management estimates FDA clearance within approximately 6 months RA'ANANA, Israel , Sept. 13, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd.

Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization

The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.

Inspira (IINN) Advances Foothold in Europe With Extended Deal

The extended agreement covers any European country RA'ANANA, Israel , Aug. 29, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today that it has signed a further Service Agreement to supplement its previously announced Strategic Agreement with Innovimed Sp.

Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical Devices

As of June 30, 2023, the Company had $8.9 million in cash, cash equivalents and short-term bank deposits. RA'ANANA, Israel , Aug. 10, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N.

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

RA'ANANA, Israel , Aug. 9, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

RA'ANANA, Israel , July 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, is proud to announce it has received International Organization for Standardization (ISO) 13485:2016 Standard Certification, which is the international standard for quality management systems within the medical device industry, and a requirement for EU regulatory approval.

Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval

Perfusion Solution, Inc. is a leading U.S.-based company that provides a platform of advanced medical devices, training and staffing to leading U.S. hospitals. RA'ANANA, Israel , July 19, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N.

Inspira™ Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.

RA'ANANA, Israel , June 15, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, is thrilled to present our latest investor deck (the "Investor Deck"), unveiling unparalleled opportunities that have the potential to reshape the acute respiratory care landscape introducing empowered breathing without the use of lungs.

Inspira™ Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care

Dr. Nir is a clinical strategy expert with market experience RA'ANANA, Israel , May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO").

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

As of March 31, 2023, the Company had $11.5 million in cash, cash equivalents, and short-term bank deposits RA'ANANA, Israel , May 18, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the first quarter ended March 31, 2023.

Inspira™ Technologies Reports First Quarter 2023 Financial Results

The ELSO conference is a consortium of healthcare institutions, researchers, and industry partners RA'ANANA, Israel , May 16, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today it will reveal the new ALICE™ device at the world's largest Extracorporeal Life Support Organization (ELSO) conference, the 34th Annual ELSO Conference in Seattle, Washington, which will be held between the 28th of September and the 1st of October 2023.

Inspira™ Technologies will Reveal the New ALICE™ Device at the World's Largest Extracorporeal Life Support Conference

Total addressable market is currently estimated at $1.16 billion RA'ANANA, Israel , May 11, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, today announced the development of the VORTX™ Blood Oxygenator, an Augmented Respiration Technology based on a new breakthrough technological approach, being designed with the intent to imitate the function of the lung, by efficiently saturating the blood with oxygen and removing carbon dioxide.

Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Genius Group Ltd

ORLANDO, FL / ACCESSWIRE / May 5, 2023 / RedChip Companies will air new interviews with Inspira Technologies OXY B.H.N. Ltd. (Nasdaq:IINN, IINNW) and Genius Group Limited (NYSE American:GNS) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 6, at 7 p.m.

Inspira Technologies and Genius Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

RA'ANANA, ISRAEL / ACCESSWIRE / April 24, 2023 / Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today that Joe Hayon, President and Co-Founder of Inspira Technologies, will present at the 2023 Planet MicroCap Showcase in Las Vegas this week on Wednesday at 14:30 CST, April 26, 2023.

Inspira(TM) Technologies to Present at the Planet MicroCap Showcase 2023 on Wednesday, April 26, 2023 in Las Vegas

As of December 31, 2022, the Company had $13.9 million in cash, cash equivalents, and deposits.  RA'ANANA, Israel , April 4, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N.

Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results

First use of HYLA in a patient undergoing open-heart surgery at Sheba Medical Center in Israel RA'ANANA, Israel , March 22, 2023 /PRNewswire/ --  Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel.

Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study

The clinical study is planned for Q1-2023 to be performed on patients undergoing open-heart surgery at Sheba Medical Center RA'ANANA, Israel , Feb. 13, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company creating new acute respiratory care technologies, announced today that it has received approval by the Ethics Committee at Sheba Medical Center in Israel to conduct a clinical study of its HYLA blood sensor in patients undergoing open-heart surgery.

News for Inspira Technologies Oxy BHN Ltd Stock (IINN)